CN1872053B - 一种瑞香素滴丸及其制备方法 - Google Patents
一种瑞香素滴丸及其制备方法 Download PDFInfo
- Publication number
- CN1872053B CN1872053B CN2005100136341A CN200510013634A CN1872053B CN 1872053 B CN1872053 B CN 1872053B CN 2005100136341 A CN2005100136341 A CN 2005100136341A CN 200510013634 A CN200510013634 A CN 200510013634A CN 1872053 B CN1872053 B CN 1872053B
- Authority
- CN
- China
- Prior art keywords
- daphnetin
- drop
- fine powder
- drop pill
- xylitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000006187 pill Substances 0.000 title claims abstract description 134
- ATEFPOUAMCWAQS-UHFFFAOYSA-N 7,8-dihydroxycoumarin Chemical compound C1=CC(=O)OC2=C(O)C(O)=CC=C21 ATEFPOUAMCWAQS-UHFFFAOYSA-N 0.000 title claims abstract description 108
- YBGKGTOOPNQOKH-UHFFFAOYSA-N daphnetin Natural products OC1=CC=CC2=C1OC(=O)C=C2O YBGKGTOOPNQOKH-UHFFFAOYSA-N 0.000 title claims abstract description 108
- 238000002360 preparation method Methods 0.000 title claims description 30
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000002671 adjuvant Substances 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 60
- 239000000843 powder Substances 0.000 claims description 59
- 239000003814 drug Substances 0.000 claims description 51
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 43
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 43
- 239000000811 xylitol Substances 0.000 claims description 43
- 235000010447 xylitol Nutrition 0.000 claims description 43
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 43
- 229960002675 xylitol Drugs 0.000 claims description 43
- 238000002156 mixing Methods 0.000 claims description 38
- 229920002472 Starch Polymers 0.000 claims description 31
- 239000008107 starch Substances 0.000 claims description 31
- 235000019698 starch Nutrition 0.000 claims description 31
- 238000009413 insulation Methods 0.000 claims description 27
- 238000010438 heat treatment Methods 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 26
- 238000002844 melting Methods 0.000 claims description 26
- 230000008018 melting Effects 0.000 claims description 26
- 238000003756 stirring Methods 0.000 claims description 26
- 239000002826 coolant Substances 0.000 claims description 25
- 229920002545 silicone oil Polymers 0.000 claims description 22
- 229940057995 liquid paraffin Drugs 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 206010043540 Thromboangiitis obliterans Diseases 0.000 abstract description 3
- 208000029078 coronary artery disease Diseases 0.000 abstract description 3
- 208000019553 vascular disease Diseases 0.000 abstract description 3
- 239000000758 substrate Substances 0.000 description 27
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 18
- 239000008101 lactose Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 15
- 235000010489 acacia gum Nutrition 0.000 description 13
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- -1 hydroxypropyl Chemical group 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000006225 natural substrate Substances 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 230000035943 smell Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 208000033386 Buerger disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241001411320 Eriogonum inflatum Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100136341A CN1872053B (zh) | 2005-06-01 | 2005-06-01 | 一种瑞香素滴丸及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100136341A CN1872053B (zh) | 2005-06-01 | 2005-06-01 | 一种瑞香素滴丸及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1872053A CN1872053A (zh) | 2006-12-06 |
CN1872053B true CN1872053B (zh) | 2010-11-03 |
Family
ID=37482764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005100136341A Expired - Fee Related CN1872053B (zh) | 2005-06-01 | 2005-06-01 | 一种瑞香素滴丸及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1872053B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110433158A (zh) * | 2019-08-14 | 2019-11-12 | 西安交通大学 | 瑞香素在制备改善主动脉内皮细胞功能的药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1493280A (zh) * | 2003-09-10 | 2004-05-05 | 南昌弘益科技有限公司 | 瑞香素滴丸及其制备方法 |
-
2005
- 2005-06-01 CN CN2005100136341A patent/CN1872053B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1493280A (zh) * | 2003-09-10 | 2004-05-05 | 南昌弘益科技有限公司 | 瑞香素滴丸及其制备方法 |
Non-Patent Citations (2)
Title |
---|
王巍.新基质复方丹参滴丸的研究.中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑 2005年第1期.2005,(20051),第11页结论,第12页第1-2行. |
王巍.新基质复方丹参滴丸的研究.中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑 2005年第1期.2005,(20051),第11页结论,第12页第1-2行. * |
Also Published As
Publication number | Publication date |
---|---|
CN1872053A (zh) | 2006-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1872075B (zh) | 一种雪胆素滴丸及其制备方法 | |
CN1872053B (zh) | 一种瑞香素滴丸及其制备方法 | |
CN1872052B (zh) | 一种辛伐他汀滴丸及其制备方法 | |
CN101194910A (zh) | 一种含乙酰天麻素的滴丸及其制备方法 | |
CN1872050B (zh) | 一种水飞蓟素滴丸及其制备方法 | |
CN1872071B (zh) | 一种增强机体免疫力和抗衰老的药物及其制备方法 | |
CN1872137B (zh) | 一种绞股篮总甙滴丸及其制备方法 | |
CN1872036B (zh) | 一种鹤草酚滴丸及其制备方法 | |
CN1872045B (zh) | 一种石吊兰素滴丸及其制备方法 | |
CN1872044B (zh) | 一种治疗冠心病的药物 | |
CN1872040B (zh) | 一种阿魏酸钠滴丸及其制备方法 | |
CN1872054B (zh) | 一种醋酸香豆素滴丸及其制备方法 | |
CN1872073B (zh) | 一种齐墩果酸滴丸及其制备方法 | |
CN1872064B (zh) | 一种阿魏酸哌嗪滴丸及其制备方法 | |
CN1872112B (zh) | 一种人参茎叶总皂苷滴丸及其制备方法 | |
CN1872108B (zh) | 一种积雪草总苷滴丸及其制备方法 | |
CN1872080B (zh) | 一种黄夹苷滴丸及其制备方法 | |
CN101194904B (zh) | 一种含马来酸哌克昔林的滴丸及其制备方法 | |
CN1872318B (zh) | 一种莪术油滴丸及其制备方法 | |
CN1872062B (zh) | 一种黄藤素滴丸及其制备方法 | |
CN101194907B (zh) | 一种含那可丁的滴丸及其制备方法 | |
CN1872059B (zh) | 一种苦参碱滴丸及其制备方法 | |
CN1872261B (zh) | 一种血竭细粉滴丸及其制备方法 | |
CN1872030B (zh) | 一种抗癌药物滴丸及其制备方法 | |
CN100592910C (zh) | 一种香菇多糖滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARM. CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101103 Termination date: 20190601 |
|
CF01 | Termination of patent right due to non-payment of annual fee |